← back to search

Nitzan Rosenfeld

Queen Elizabeth Hospital · GB
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Molecular Biology Techniques and Applications, and Genetic factors in colorectal cancer.
h-index
55
citations
26,044
works
200
NIH funding
primary concept
Medicine
email

Recent publications

Personalized ctDNA analysis for detection of residual disease and recurrence in surgically treated HNSCC patients
npj Precision Oncology 2026cited by 1position: middledoi
ctDNA monitoring using tumor-informed copy number analysis.
2026cited by 0position: contributordoi
Cell-free DNA size deconvolution resolves nucleosomal origins and reveals tumor-associated fragmentomic alterations.
2026cited by 0position: contributordoi
ctDNA monitoring using tumor-informed copy number analysis
EMBO Molecular Medicine 2026cited by 0position: middledoi
Cell-free DNA size deconvolution resolves nucleosomal origins and reveals tumor-associated fragmentomic alterations
Nature Communications 2026cited by 0position: middledoi
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests
Nature Reviews Clinical Oncology 2025cited by 25position: lastdoi
A standardized framework for robust fragmentomic feature extraction from cell-free DNA sequencing data
Genome biology 2025cited by 17position: middledoi
Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study
PLoS Medicine 2025cited by 10position: middledoi
A large‐scale retrospective study in metastatic breast cancer patients using circulating tumour <scp>DNA</scp> and machine learning to predict treatment outcome and progression‐free survival
Molecular Oncology 2025cited by 5position: middledoi
260 Second Primary Lung Cancer Cohort Study (SPORT)
Lung Cancer 2025cited by 0position: middledoi
Detecting circulating tumor DNA in archived whole blood samples in patients undergoing treatment for primary cutaneous melanoma
EJC Skin Cancer 2025cited by 0position: middledoi
Abstract 4550: Dried blood sot sampling as a minimally invasive and accessible method for investigating circulating tumor DNA in diverse cancer settings
Cancer Research 2025cited by 0position: lastdoi
A mathematical model of cell-free DNA fragment size reveals cancer-specific fragmentomic patterns
Research Square 2025cited by 0position: middledoi
Genomic Profiles of Early-Stage Non-Small Cell Lung Cancer Patients, and Association with Pre-Treatment Blood Circulating Tumour DNA Detection and Levels
The Journal of Liquid Biopsy 2025cited by 0position: lastdoi
Second Primary Lung Cancer – An Emerging Issue in Lung Cancer Survivors
Journal of Thoracic Oncology 2024cited by 26position: middledoi
LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer
Journal of Thoracic Oncology 2024cited by 11position: middledoi
Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer
European Urology 2024cited by 11position: middledoi
Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer
International Journal of Gynecological Cancer 2024cited by 8position: middledoi
HERD: A multi-centre prospective cohort study to facilitate early detection of relapse in radically treated, high risk head and neck squamous cell carcinoma.
Journal of Clinical Oncology 2024cited by 0position: middledoi
S138 Multiparametric investigation and stratification of indeterminate lung nodules (MISIL1)
2024cited by 0position: middledoi
Second Primary Lung Cancer—Potential Areas of Ambiguity
Journal of Thoracic Oncology 2024cited by 0position: middledoi
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
Nature Medicine 2023cited by 75position: middledoi
Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer
Nature Communications 2023cited by 65position: middledoi
Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer
EMBO Molecular Medicine 2023cited by 56position: middledoi
Comparison of tumor-informed and tumor-naïve sequencing assays for ctDNA detection in breast cancer.
2023cited by 51position: contributordoi
Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer.
2023cited by 46position: contributordoi
Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
Nature Medicine 2023cited by 7position: middledoi
235TiP Hamlet.rt Trans: Prospective single-centre translational study evaluating liquid biomarkers of radiation response
Annals of Oncology 2023cited by 2position: middledoi
Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.
2023cited by 1position: contributordoi
A large-scale retrospective study in metastatic breast cancer patients using circulating tumor DNA and machine learning to predict treatment outcome and progression-free survival
bioRxiv (Cold Spring Harbor Laboratory) 2023cited by 1position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Davina Gale · AstraZeneca (United Kingdom)33 papers (2012–2025)Christopher G. Smith · University of Cambridge23 papers (2017–2025)Katrin Heider · Federal Office of Consumer Protection and Food Safety22 papers (2017–2023)Florent Moulière · Cancer Research UK Manchester Institute21 papers (2016–2022)Wendy N. Cooper · Queen Mary University of London21 papers (2019–2026)James D. Brenton · University of Cambridge20 papers (2012–2025)Jonathan C. M. Wan · The Francis Crick Institute16 papers (2017–2025)Robert C. Rintoul · University of Cambridge15 papers (2017–2025)Dineika Chandrananda · The University of Melbourne14 papers (2017–2022) · 14 papers (2020–2026)Charles Massie · University of Cambridge12 papers (2017–2024)Carlos Caldas · Concern Foundation12 papers (2012–2025)Hui Zhao · Jiangnan University11 papers (2021–2026)James Morris · Cardiff and Vale University Health Board11 papers (2017–2022)Karen Howarth · University of Bradford10 papers (2017–2026)Francesco Marass · SIB Swiss Institute of Bioinformatics10 papers (2013–2020)Anna Piskorz · University of Cambridge9 papers (2012–2020)Matthew Eldridge · Cancer Research UK Cambridge Center9 papers (2019–2025)Susan Harden · Alfred Health9 papers (2017–2022)Christine Parkinson · Addenbrooke's Hospital9 papers (2012–2018)